Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...

Following treatment with TG Therapeutics’ Briumvi, patients reported improvements in satisfaction and quality of life.

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...

When trial results for a novel cancer drug were trumpeted in July, the rheumatology field felt the ripples. The drug is ofatumumab, a monoclonal antibody (mAb) targeting the CD20 molecule on B ...

Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis. Despite this, the function of ...

In a recent study posted to the medRxiv* preprint server, researchers assessed the efficacy of a third dose of coronavirus disease 2019 (COVID-19) vaccine in anti-CD20 antibody-treated individuals.

Seventeen patients with R/R MCL received a single dose of LV20.19 CAR T cells at 2.5 × 10 6 cells/kg (phase I = three patients; phase II = 14 patients). The best overall response rate (ORR) was 100% ...

Clinicopathologic features and outcomes of de novo transformed indolent lymphoma. CNS involvement by North American-ATLL (NA-ATLL) is associated with discrete patterns and molecular profile involving ...

MRD-guided retreatment with anti-CD20 antibodies may improve survival outcomes in high-risk, relapsed CLL patients by initiating therapy before clinical relapse. The study showed MRD-triggered ...